PharmaCyte Biotech, Inc. (PMCB) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2026, PharmaCyte Biotech reported revenue of $0. Net income was -$19.4M, or -$2.77 per diluted share. Operating activities generated -$5.2M of cash. At fiscal year end, PharmaCyte Biotech held $46.8M in total assets against $11.8M in total liabilities, including $18.6M of cash and equivalents.
Open the full interactive PharmaCyte Biotech financials → Quarterly statements, key ratios, valuation history and price charts.
PharmaCyte Biotech Key Stats
| Share Price | $0.36 |
|---|---|
| Market Cap | $3.8M |
| 52-Week Range | $0.36 – $1.22 |
| Shares Outstanding | 10.7 million (basic, 2027 Q1) |
PharmaCyte Biotech Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$3.6M | -$4.4M | -$6.5M | -$8.5M | -$4.4M | -$6.9M |
| Pre-Tax Income | -$3.6M | -$4.2M | -$4.3M | $333,763 | $30.7M | -$19.4M |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$3.6M | -$4.2M | -$4.3M | $333,763 | $30.7M | -$19.4M |
| Diluted EPS | -$2.45 | -$0.27 | -$0.22 | -$1.80 | $3.19 | -$2.77 |
PharmaCyte Biotech Quarterly Results
| 2026 Q2 | 2026 Q3 | 2026 Q4 | 2027 Q1 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$7.4M | $746,860 | -$4.4M | -$5.1M |
| Diluted EPS | -$1.24 | -$0.17 | -$0.52 | -$0.54 |
PharmaCyte Biotech Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | — | — | $68.0M | $50.2M | $15.2M | $18.6M |
| Current Assets | $2.3M | $85.5M | $68.1M | $50.4M | $22.4M | $37.4M |
| Total Assets | $7.4M | $90.6M | $73.3M | $59.9M | $55.2M | $46.8M |
| Current Liabilities | $724,778 | $704,370 | $586,581 | $7.4M | $2.9M | $826,424 |
| Total Liabilities | $724,778 | $704,370 | $586,581 | $20.4M | $3.3M | $11.8M |
| Shareholders' Equity | $6.7M | $89.9M | $72.7M | $27.6M | $51.9M | $33.3M |
PharmaCyte Biotech Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$3.3M | -$4.1M | -$3.8M | -$2.2M | -$3.0M | -$5.2M |
| Cash From Investing | $0 | $0 | $0 | -$5.0M | -$7.0M | $2.0M |
| Cash From Financing | $4.6M | $87.3M | -$13.6M | -$10.7M | -$25.0M | $6.6M |
Figures from PharmaCyte Biotech's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full PharmaCyte Biotech financials page for every line item.
PharmaCyte Biotech Company Profile
| Ticker | PMCB |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Las Vegas, Nevada |
| Incorporated in | Nevada |
| Fiscal Year End | April 30 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001157075 |
Frequently Asked Questions
What was PharmaCyte Biotech's revenue in fiscal 2026?
PharmaCyte Biotech (PMCB) reported revenue of $0 for fiscal 2026.
What is PharmaCyte Biotech's annual revenue history?
PharmaCyte Biotech's annual revenue by fiscal year: 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0; 2026: $0.
What was PharmaCyte Biotech's net income in fiscal 2026?
PharmaCyte Biotech reported net income of -$19.4M for fiscal 2026.
What was PharmaCyte Biotech's earnings per share (EPS) in fiscal 2026?
PharmaCyte Biotech's diluted EPS was -$2.77 for fiscal 2026 (adjusted for any later stock splits).
What was PharmaCyte Biotech's revenue last quarter?
In its most recent reported quarter (2027 Q1), PharmaCyte Biotech reported revenue of $0.
How many shares of PharmaCyte Biotech are outstanding?
PharmaCyte Biotech reported a weighted average of 10.7 million basic shares outstanding in 2027 Q1.
What is PharmaCyte Biotech's market cap?
Based on its latest closing price, PharmaCyte Biotech (PMCB) has a market capitalization of about $3.8M.
When does PharmaCyte Biotech's fiscal year end?
PharmaCyte Biotech's fiscal year end, as registered with the SEC, is April 30.
Where is PharmaCyte Biotech headquartered?
PharmaCyte Biotech lists its business address in Las Vegas, Nevada in its SEC filings.
PharmaCyte Biotech Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →